Vixtimotamab
Based on 1 Customer Validation
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.29%
- CAS 番号: 2243775-32-6
- 分子量:103.14 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
[V-kappa-VH-V-lambda-VH']-noncovalent dimer (tandem diabody)
Human
CD3E & CD33
Vixtimotamab (TandAb T564; 24 h) induces CD25 and CD69 with EC50s of 1 pM and 2 pM, respectively[1].
Vixtimotamab (TandAb T564; 4 days) induces T-cell proliferation in PBMCs with an EC50 of 3 pM[1].
Vixtimotamab (TandAb T564; 25 pM, 48 h) shows cytotoxicity against HL-60 and KG-1a cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60 and KG-1a cells
-
Concentration:25 pM
-
Incubation Time:48 h
-
Result:Showed cytotoxicity of 86.0±1.4% and 81.3±1.5% against HL-60 and KG-1a cells, respectively.
Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) substantially inhibits tumor growth in an established HL-60 xenograft NOD/scid mouse model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-week-old NOD/scid female mice, weighing 20.7 ± 1.48 g, prophylactic HL-60 graft model[1]
-
Dosage:0.1, 1, or 10 μg/mouse
-
Administration:Intravenous injection, on days 0, 1, 2, 3, and 4
-
Result:Demonstrated dose-dependent tumor growth delay.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
[V-kappa-VH-V-lambda-VH']-noncovalent dimer (tandem diabody)
ELISA, FACS, Functional assay
-
Immobilized Vixtimotamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC50 for this effect is 4.95 ng/mL. -
Immobilized Vixtimotamab can bind Human Siglec-3/CD33 Protein (ECD, His Tag). The EC50 for this effect is 4.95 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Vixtimotamab (HY-P99958). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow cytometric analysis of 1X106 THP-1 cells labeling CD33 with Vixtimotamab (HY-P99958, red). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF488-conjugated Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 2243775-32-6
-
性状 Liquid
-
分子量 103.14 kDa
-
Color Colorless to light yellow
-
SMILES
[Vixtimotamab]
-
別名
AMV-564; TandAb T564
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)